Viking Therapeutics has seen its share price move sharply over the past several years, which puts a spotlight on whether the current valuation lines up with the strength of its balance sheet. With the stock now trading at US$28.44, the key issue is how that market value stacks up against the company’s book value compared with the wider biotech industry.
- Over the past 5 years the stock has returned about 391.2%, so many future expectations may already be embedded in the current market price and raise clear questions about how its book value supports that move.
- Viking Therapeutics plans to present new clinical data on its VK2735 obesity program at ObesityWeek 2026, which can influence how investors think about future cash generation and in turn how much of a premium or discount to book value they are willing to pay today.
- The analysts covering Viking Therapeutics have run their own numbers. See what analysts think Viking Therapeutics's shares could be worth.
The issue now is whether the share price at US$28.44 is justified by Viking Therapeutics’ book value when set against the industry average.
If you want to stress test this same book value question beyond Viking Therapeutics, compare it against other 32 high quality undervalued stocks.
Is Viking Therapeutics Getting Expensive on Book Value?
P/B suits Viking Therapeutics because it is still in a loss making phase where the balance sheet does more of the heavy lifting than current earnings. At a P/B of 6.2x, the stock trades well above the broader Biotechs sector average of about 1.9x, although it sits below the peer group reference point of roughly 7.3x. That gap to the industry indicates that investors are already willing to pay a sizeable premium over the company’s book value.
News around the VK2735 data presentations at ObesityWeek 2026 keeps attention on Viking Therapeutics’ pipeline. However, the 6.2x multiple still prices the shares at an expensive level compared with the typical biotech balance sheet. The valuation model used here heavily penalises ongoing losses, so the sizeable spread to the sector benchmark reads more as a warning signal on how much optimism is embedded in the equity than a precise estimate of mispricing. Explore the numbers behind Viking Therapeutics's P/B valuation.
The Viking Therapeutics Narrative: What Would Justify Today's Price?
Simply Wall St Narratives take Viking Therapeutics' valuation puzzle a step further by spelling out what future growth, margins and earnings paths would need to look like for the stock to be worth materially more or less than today’s price. Each one treats fair value as a thesis about the business that can be tracked over time rather than a single static number, and all are hosted on the Community page.
One of the top narratives on Viking Therapeutics: 77% undervalued
This Narrative is the bullish analyst Narrative on Simply Wall St, built on the most optimistic analyst price target and forecasts, not one person's view.
"VK2735’s maintenance data, with roughly 16 to 19% weight loss over 21 weeks and high proportions of patients reaching double digit weight loss, opens the door to differentiated labeling and pricing power…"
Discover why this Narrative puts Viking Therapeutics at 77% undervalued.
For Viking Therapeutics, the share price is only one piece of the real decision
Before you put too much weight on any valuation model for Viking Therapeutics, it pays to ask who is steering the ship, how their pay packets are structured, and whether those incentives truly line up with your own. See who runs Viking Therapeutics and how they are paid.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com